Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group;Comment minimiser les risques associes à un allongement significatif de l'intervalle QTc chez les personnes souffrant de schizophrenie recommandations consensuelles du Cardiac Safety in Schizophrenia Group (CSISG)

Encephale

Volumn 28, Issue 6 I, 2002, Pages 552-562

  Ames, D ^c   Camm, J ^c   Cook, P ^a   Falkai, P ^c   Gury, C ^c   Hurley, R ^c   Johnson, G ^c   Piepho, R ^c   Vieweg, V ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b Universite Virginia Commonwealth   (United States)

^c NONE

Author keywords

Antipsychotic agents; Arrhythmia; Consensus statement; Prolongation of QTc interval; Torsades de pointes

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CHLORAL HYDRATE; CHLORPROMAZINE; CIMETIDINE; CIPROFLOXACIN; CLOMIPRAMINE; CLOZAPINE; DESIPRAMINE; DOXEPIN; DROPERIDOL; ENOXACIN; HALOPERIDOL; IMIPRAMINE; LITHIUM; MAPROTILINE; MESORIDAZINE; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; RITONAVIR; SERTINDOLE; SULPIRIDE; SULTOPRIDE; THIORIDAZINE; TRIFLUOPERAZINE; UNINDEXED DRUG;

ACCIDENTAL DEATH; AGGRESSION; ALCOHOLISM; ARTICLE; BODY WEIGHT DISORDER; CARDIOTOXICITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; DIET; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GLUCOSE INTOLERANCE; HEART BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PROARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPONATREMIA; INCIDENCE; ISCHEMIA; LIFE EXPECTANCY; LIFESTYLE; LONG QT SYNDROME; MORBIDITY; MORTALITY; MYOCARDITIS; ORTHOSTATIC HYPOTENSION; POLYDIPSIA; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SCHIZOPHRENIA; SINUS NODE DISEASE; SMOKING; SUBSTANCE ABUSE; SUICIDE; TORSADE DES POINTES; TREATMENT OUTCOME; VIOLENCE;

EID: 0036875535     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. ALLISON DB, MENTORE JL, HEO M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156: 1686-96.
2. APPROVAL LETTER AND LABELING. Ziprasidone label (IM), Sweden 2000.
3. APPROVAL LETTER AND LABELING. Ziprasidone label (oral), Sweden 2000.
4. BEDNAR MM, HARRIGAN EP, ANZIANO RJ et al. The QT interval. Prog Cardiovasc Dis 2001; 43 (Suppl 1): 1-45.
5. BROWN S, BIRTWISTLE J, ROE L et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29: 679-701.
6. BUCKLEY NA, SANDERS N. Cardiovascular adverse effects of antipsychotic Drugs. Drug Safety 2000; 23: 215-28.
7. CHAKOS M, LIEBERMAN J, HOFFMAN E et al. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158: 518-26.
8. CHVILICEK JP, HURLBERT BJ, HILL GE. Diuretic-induced hypokalemia inducing torsades de pointes. Can J Anaesth 1995; 42: 1137-9.
9. COLLABORATIVE WORKING GROUP ON CLINICAL TRIAL EVALUATIONS. Adverse effects of the atypical antipsychotics. J Clin Psychiatry 1998; 59 (Suppl 12): 17-22.
10. COMPTON SJ, LUX RL, RAMSEY MR et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996; 94: 1018-22.
11. COOKE RA, CHAMBERS JB, SINGH R etal. QT interval in anorexia nervosa. Br Heart J 1994; 72: 69-73.
12. CPMP. Points to consider: the assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. EMEA London, England. Human Medicines Evaluation Unit, 1997.
13. CSM/MCA. Cardiac arrhythmias with pimozide (Orap). Cur Probl Pharmacovigil 1995; 21: 1.
14. CSM/MCA. Suspension of availability of sertindole (serdolect). Curr Probl Pharmacovigil 1999; 25: 1.
15. CZEKALLA J, BEASLEY CM, DELLVA MA et al. Analysis of the QTc interval during olanzapine treatment of patients with schizophrenia and related psychosis. J Clin Psych 2001; 62: 191-8.
16. DEAR DOCTOR LETTER, MESORIDAZINE. Novartis/FDA, 22 September 200.
17. DROLET B, ZHANG S, DESCHÊNES D et al. Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. J Cardiovasc Electrophysiol 1999; 10: 1597-604.
18. FDA MEMORANDUM, 14th June 2000. Ziprasidone NDA #20825, Study Report of Clinical Pharmacology Protocol #128-054.
19. GOLDSTEIN JM, BORISON R, ARVANITIS L et al. Seroquel: a putative atypical antispychotic drug with serotonin and dopamine receptor agonist properties. Preclinical and early clinical trials in schizophrenia. J Clin Psychiatry 1995; 56: 438-45.
20. GURY C, CANCEIL O, IARIA P. Antipsychotic drugs and cardiovascular safety: current studies of prolonged QT interval and risk of ventricular arrhythmia. Encephale 2000; 26: 62-72.
21. HATTA K, TAKAHASHI T, NAKAMURA H et al. Hypokalemia and agitation in acute psychotic patients. Psych Res 1999; 86: 85-8.
22. HATTA K, TAKAHASHI T, NAKAMURA H et al. Prolonged QT interval in acute psychotic patients. Psych Res 2000; 94: 279-85.
23. HAVERKAMP W, BREITHARDT G, CAMM J et al. The potential for QT prolongation and pro-arrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47: 219-33.
24. JESTE DZ, GLADSJO JA, LINDAMER LA et al. Medical comorbidity in schizophrenia. Schizophr Bull 1996; 22: 413-30.
25. KANG UG, KWON JS, AHN YM et al. Electrocardiographic abnormalities in patients treated with clozapine. J Clin Psychiatry 2000; 61: 441-6.
26. KAPUR S, REMINGTON G. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Ann Rev Med 2001; 52: 503-17.
27. LADER M. Some adverse effects of antipsychotics: prevention and treatment. J Clin Psychiatry 1999; 60 (Suppl 12): 18-21.
28. LEFF J, SARTORIUS N, JABLENSKY A et al. The international pilot study of schizophrenia: five-year follow-up findings. Psychol Med 1992; 22: 131-45.
29. LISCHKE V, BEHNE M, DOELKEN P et al. Droperidol causes a dose-dependant prolongation of the QT interval. Anesth Analg 1994; 79: 983-6.
30. MORGANROTH J, BROWN AM, CRITZ S et al. Variability of the QT measurement in healthy men with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991; 67: 774-7.
31. NEWMAN SC, BLAND RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry 1991; 36: 239-45.
32. PASSMAN R, KADISH A. Polymorphic ventricular tachycardia, long QT syndrome, and torsades de pointes. Med Clin North Am 2001; 85: 321-41.
33. RADOMSKY ED, HAAS GL, MANN JJ et al. Suicidal behaviour in patients with schizophrenia and other psychotic disorders. Am J Psychiatry 1999; 156: 1590-5.
34. RAUTAHARJU PM, ZHOU SH, WONG S et al. Sex differences in the evolution of the electrocardiographic QT interval with age. Can J Cardiol 1992; 8: 690-5.
35. REILLY JG, AYIS SA, FERRIER IN et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355: 1048-52.
36. REPORT OF THE WORKING GROUP OF THE ROYAL COLLEGE OF PSYCHIATRISTS' PSYCHOPHARMACOLOGY SUB-GROUP. The association between antipsychotic drugs and sudden death. Council report CR57, January 1997.
37. SARMA JS, VENKATARAMAN K, NICOD P et al. Circadian rhythmicity of rate-normalized QT interval in hypothyroidism and its significance for development of class III antiarrhythmic agents. Am J Cardiol 1990; 66: 959-63.
38. SHERIDAN DJ. Drug-induced proarrhythmic effects: assessment of changes in QT interval. Br J Clin Pharmacol 2000; 50: 297-302.
39. VINCENT GM, TIMOTHY K, FOX J et al. The inherited long QT syndrome: from ion channel to bedside. Cardiol Rev 1999; 7: 44-55.
40. WADDINGTON JL, YOUSSEF HA, KINSELLA A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study. Br J Psychiatry 1998; 173: 325-9.
41. WILTON LV, HEELEY EL, PICKERING RM et al. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing suveillance studies of sertindole and two other atypical drugs: risperidone and olanzapine. J Psychopharmacol 2001; 15: 120-6.
42. WOOSLEY R, SKETCH MH. Gender and drug-induced Torsades de pointes. Acc Current J Rev 1999; 30: 18-9.